(Reuters) - Antigenics, whose shares rose 35 percent in morning trade, said data from a trial of 12 patients with glioblastoma, or late-stage brain cancer, showed the vaccine boosted the immune systems of all 12 patients and appears to be helping improve survival.
While the trial is extremely small, it is potentially significant because no cancer therapy has been shown to consistently boost the body's immune system in such a way that it can become a primary weapon in attacking the disease.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment